GIP receptor antagonist and GLP-1 receptor agonist
Maridebart cafraglutide 140 mg injection every 4 weeks
MARI_SC_140MG_Q4W
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.70 (0.01 to 55.25) | 0.57 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.66 (0.01 to 50.87) | 0.64 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 7.19 (1.51 to 42.41) | 0.26 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 8.14 (1.38 to 60.47) | 0.31 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.30 (0.12 to 34.92) | 0.45 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 9.96 (0.79 to 179) | 0.15 |